Humira to be launched in Korea

Abbott Korea said on December 18 that it will launch HUMIRA (adalimumab), a human-derived antibody that binds to human tumor necrosis factor alpha (TNF alpha), from next year, as its efficacy and safety were assessed in the local double-blind, placebo-controlled studies in adult patients.

HUMIRA is approved for reducing the signs and symptoms, inducing major clinical response, slowing the pr...